ArticleBioconjugate chemistry2026
Engineering Light-Responsive Transcription Factors via Strategic Masking of Post-translational Modification Residues.
Article in Bioconjugate chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advancing protein engineering via organic chemistry.Communications chemistry · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of synthetic transcription factors (TFs) that generate functional outputs in response to specific stimuli holds significant promise for modulating key cellular processes in both basic research and biomedical applications. Here, we rationally designed synthetic TFs bearing reversible modifications that mimic post-translational modifications regulatory mechanisms. By combining native chemical ligation (NCL) with palladium-mediated C-S cross-coupling, we synthesized a caged Max variant in which key residues (e.g., Lys31/57) were masked with o-nitroveratryloxycarbonyl groups. While the preparation of photoreactive proteins is generally incompatible with traditional NCL-desulfurization approaches, our strategy highlights the power of integrating total synthesis with late-stage transformations to access novel photoreactive proteins. Remarkably, whereas the engineered caged Max displayed a pronounced reduction in DNA-binding activity, potent binding to the enhancer box was rapidly restored upon site-selective unmasking of Lys31/57. The caged Max can be efficiently activated on-demand within minutes by simple in situ photolysis, enabling precise modulation of its DNA-binding activity. Our approach provides an effective means for producing and activating TF proteins, paving the way for light-responsive TF analogs with on-demand control across diverse applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.